
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HCR-188
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Helicore Doses First Participant in Phase 1 Trial of HCR-188 for Obesity
Details : HCR-188 is a first-in-class GIP antagonist, antibody candidate, which is currently being evaluated for the treatment of obesity.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 25, 2025
Lead Product(s) : HCR-188
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HCR-188
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HCR-188 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 25, 2025
Lead Product(s) : HCR-188
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
